Document Detail

Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion.
MedLine Citation:
PMID:  15899958     Owner:  NLM     Status:  MEDLINE    
CONTEXT: Because surgical and medical therapies of acromegaly all have specific limitations, radiotherapy has been used as an adjunctive strategy. Stereotactic radiosurgery has not yet been widely evaluated. OBJECTIVE: The objective was to perform an analysis of long-term hormonal effects and tolerance of gamma knife radiosurgery. DESIGN: Eighty-two patients were prospectively studied over a decade, with a mean follow-up of 49.5 months. SETTING: All patients were treated at the Department of Functional Neurosurgery of Marseille, France. PATIENTS: The patients included 82 with active acromegaly, of whom 63 had previous transsphenoidal surgery. INTERVENTION: Intervention included radiosurgery using the Leksell Gamma Unit B model. MAIN OUTCOME MEASURES: Remission was diagnosed when mean GH levels were less than 2 ng/ml and IGF-I was normal for age off somatostatin agonists (at least 3 months). RESULTS: Seventeen percent of the patients were in remission without any treatment. Twenty-three percent previously uncontrolled on somatostatin agonists fulfilled the same criteria after gamma knife while maintained on medical treatment. Initial GH and IGF-I levels off somatostatin agonists were significantly higher in uncured than in remission group (P = 0.01 and 0.047, respectively). Withdrawal of somatostatin agonists at the time of radiosurgery had no incidence on the outcome. No significant difference was found in success rate whether patients had previously been treated or not. Long-term side effects included complete (n = 2) or partial (n = 12) hypopituitarism diagnosed 1-7 yr after gamma knife. CONCLUSIONS: Gamma knife radiosurgery may represent a therapeutic approach in patients with moderate initial or residual GH hypersecretion.
Frédéric Castinetti; David Taieb; Jean-Marc Kuhn; Philippe Chanson; Manabu Tamura; Philippe Jaquet; Bernard Conte-Devolx; Jean Régis; Henry Dufour; Thierry Brue
Related Documents :
22956348 - Efficacy of low dose hcg on oocyte maturity for ovarian stimulation in poor responder w...
11596958 - Population-based analysis of arteriovenous malformation treatment.
7489688 - Prognostic significance of central motor conduction on the non-hemiplegic side in supra...
3354358 - Intracranial meningiomas in the elderly (over 70 years old). a retrospective study of 3...
24593838 - Efficacy and safety of low molecular weight heparin in patients with mechanical heart v...
22424708 - Flap design and mandibular third molar surgery: a split mouth randomized clinical study.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2005-05-17
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  90     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-08-09     Completed Date:  2005-09-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4483-8     Citation Subset:  AIM; IM    
Federation of Endocrinology, Diabetes, Metabolic Diseases and Nutrition, Hôpital de la Timone, Centre Hospitalier Universitaire de Marseille and Faculté de Médecine, Université de la Méditerranée, Marseille, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acromegaly / surgery*
Adenoma / secretion,  surgery*
Follow-Up Studies
Human Growth Hormone / secretion
Middle Aged
Pituitary Neoplasms / secretion,  surgery*
Prospective Studies
Radiosurgery* / adverse effects
Remission Induction
Treatment Outcome
Reg. No./Substance:
12629-01-5/Human Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-depende...
Next Document:  Vitamin D insufficiency does not affect bone mineral density response to raloxifene.